Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

NCTNCT04027712Other idLTA_MOTS-c_bamyloid_DM_CAD

Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

Measures MOTS-c, does not give it. It appears in an outcome measure.

Overview

Status: Status unknown
Phase: Phase not stated
Enrollment: 120 participants (estimated)
Sponsor: University of Athens · Other
Design: Not stated
Countries: 1 country
Greece
Start: 1 Jan 2014
Primary completion: 31 Dec 2019 (estimated)
Completion: 31 Dec 2021 (estimated)
First posted: 22 Jul 2019
Last update posted: 23 Jul 2019
Conditions: Diabetes · Clopidogrel Resistance · Amyloid · Insulin Resistance

Timeline

1 trial

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20142016201820202022

Ph –
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
NCT04027712
1 Jan 2014 to est. 31 Dec 2021

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease

Arms0

The registry lists no arms for this trial.

Primary outcomes3

Outcomes the sponsor listed as primary.

mots-c predicts cardiovascular mortality in diabetic with coronary artery disease
Time frame · 2 year follow up
Registry description
mots-c concentration in Diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality
b amyloid predicts cardiovascular mortality in diabetic with coronary artery disease
Time frame · 2 year follow up
Registry description
b amyloid concentration in Diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality
b amyloid predicts cardiovascular mortality in diabetic with coronary artery
Time frame · 2 year follow up
Registry description
Resistance to clopidogrel as defined by Light Transmission Aggregometry in diabetic with coronary artery disease treated with acetyl-salicylic and clopidogrel predicts cardiovascular mortality.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Clinical trial · 2020

4 results

β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease.

Ikonomidis et al. 2020Journal of thrombosis and thrombolysiscited by 13

PMID 32052315DOI 10.1007/s11239-020-02060-4PUB-32052315

Full text at the publisher4 results

Publisher page See results (4)

Eligibility

Who could join, as posted.

Sex: All
Age: from 18 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * type 2 diabetic patients with coronary artery disease, documented by coronary angiography, * both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (DAPT), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study Exclusion Criteria: * abnormal renal function (creatinine\> 2.5 mg / dl), * hepatic failure (bilirubin\> 2 mg / dl), * active malignancy, * patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd, * patients with a history of hemorrhagic mood, * patients with thrombocytopenia (PLTs \< 100x109 / L) and * anemia (HCT \<28%).

PepBank is a research reference. Talk to a doctor before you use any peptide.